GNbAC1
Showing 1 - 10 of 10
Multiple Sclerosis Trial in Basel, Geneva (GNbAC1, GNbAC1 )
Completed
- Multiple Sclerosis
- GNbAC1
- GNbAC1 placebo
-
Basel, Switzerland
- +1 more
Feb 5, 2021
Multiple Sclerosis Trial (GNbAC1, GNbAC1 )
Completed
- Multiple Sclerosis
- GNbAC1
- GNbAC1 placebo
- (no location specified)
Oct 19, 2020
Multiple Sclerosis Trial in Sydney (GNbAC1, GNbAC1 Placebo)
Completed
- Multiple Sclerosis
- GNbAC1
- GNbAC1 Placebo
-
Sydney, New South Wales, AustraliaScientia Clinical Research Ltd
Oct 19, 2020
Healthy Volunteers Trial in Berlin (GNbAC1)
Completed
- Healthy Volunteers
- GNbAC1
-
Berlin, GermanyPAREXEL Early Phase Clinical Unit
Oct 19, 2020
Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (GNbAC1, Placebo)
Completed
- Multiple Sclerosis, Relapsing-Remitting
- GNbAC1
- Placebo
-
Sofia, Bulgaria
- +11 more
Oct 19, 2020
Multiple Sclerosis, Relapsing-Remitting Trial in Worldwide (GNbAC1 Monoclonal Antibody)
Terminated
- Multiple Sclerosis, Relapsing-Remitting
- GNbAC1 Monoclonal Antibody
-
Sofia, Bulgaria
- +11 more
Oct 19, 2020
Diabetes Type 1 Trial in Australia (GNbAC1, Placebo)
Completed
- Diabetes Mellitus Type 1
- GNbAC1
- Placebo
-
Macquarie University, New South Wales, Australia
- +12 more
Oct 19, 2020
Multiple Sclerosis Trial in Stockholm (Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg)
Terminated
- Multiple Sclerosis
- Temelimab 18 mg/kg
- +2 more
-
Stockholm, SwedenCenter for Neurology, Academic Specialist Center
Jul 4, 2022
Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)
Completed
- Multiple Sclerosis
- temelimab 18 mg/kg
- +3 more
-
Stockholm, SwedenCenter for Neurology, Academic Specialist Center
Jul 4, 2022
Post-COVID-19 Syndrome Trial in Geneva (Temelimab 54mg/kg, Placebo)
Not yet recruiting
- Post-COVID-19 Syndrome
- Temelimab 54mg/kg
- Placebo
-
Geneva, SwitzerlandGeneva University Hospital
Aug 9, 2022